Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
08:25am, Monday, 23'rd Mar 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday
02:05am, Monday, 09'th Mar 2026
DiaMedica Therapeutics (NASDAQ: DMAC - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect DiaMedica Therapeutics to post ea
Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33
04:02am, Saturday, 07'th Mar 2026
DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat reports. One
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
07:35am, Thursday, 05'th Mar 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
09:23am, Tuesday, 24'th Feb 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
11:03am, Tuesday, 17'th Feb 2026
Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Leon Cooperman (Trades, Portfolio) recently submitted the 13F filing for the f
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
04:46am, Saturday, 07'th Feb 2026
Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 16'th Jan 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
08:45am, Thursday, 18'th Dec 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) a
DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript
10:01am, Thursday, 13'th Nov 2025
DiaMedica Therapeutics Inc. ( DMAC ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Dietrich Pauls - President, CEO & Director Julie Krop - Chief Medical Officer Scott Kellen
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
04:30pm, Wednesday, 12'th Nov 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
08:15am, Monday, 10'th Nov 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
04:15pm, Thursday, 06'th Nov 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke,
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:15pm, Monday, 29'th Sep 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 17'th Sep 2025
Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
